⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7720292 | 0.87 | — | — | |
| SCHEMBL1104703 | 0.79 | — | — | |
| SCHEMBL22433361 | 0.76 | — | — | |
| SCHEMBL24836240 | 0.71 | — | — | |
| SCHEMBL25825051 | 0.70 | — | — | |
| SCHEMBL24835794 | 0.70 | — | — | |
| SCHEMBL21669914 | 0.69 | — | — | |
| SCHEMBL25015387 | 0.67 | — | — | |
| SCHEMBL27618427 | 0.67 | — | — | |
| SCHEMBL12044972 | 0.67 | CCR5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) | 2019-05-09 | — | — | US | disclosed |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170135926-A1 | TOPICAL COMPOSITIONS AND METHODS FOR SKIN LIGHTENING | AVON PROD INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9566224-B2 | Tyrosinase inhibitors | AVON PRODUCTS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-8168212-B2 | Topical compositions comprising non-proteogenic amino acids and methods of treating skin | AVON PRODUCTS, INC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | AVON PRODUCTS, INC. (US) | 2010-10-14 | — | — | US | disclosed |